The most recent anti-aging treatment to emerge from the research arm of the US government is a pink-colored capsule.

The capsule was developed by the University of California, Berkeley’s National Institutes of Health (NIH) and was tested on mice.

It has been used as a test of new treatments for melanoma, but it hasn’t been tested on humans.

The FDA, the US Food and Drug Administration (FDA), the US Agency for Toxic Substances and Disease Registry (ATSDR), and other regulators have approved it for use in patients with metastatic melanoma and other forms of cancer.

“This capsule has not been evaluated for human safety,” said Dr. Michael L. Fauci, director of the UC Berkeley Center for the Development and Evaluation of Therapeutics and the first director of research at the NIH.

“Its safety and efficacy are not known.”

However, the FDA approved the capsule last month.

It’s unclear if it’s still under development.

Dr. Faucicci said he was disappointed by the news.

“We are pleased to see that this capsule has been approved for use, but the process needs to be streamlined to ensure that it is safe and effective,” he said.

“It would be a mistake to rely on a clinical trial as a basis for approving a drug,” he added.

Faucicicci’s office has been tracking the capsule’s development.

It received more than 3,000 applications from researchers from different institutions, and Fauci said the FDA could approve the capsule within weeks.

However, he noted that FDA approval of the capsule would depend on whether the FDA approves the first clinical trial for its safety and effectiveness.

Fausicci expects that the FDA will wait until a new clinical trial is completed.

“Until the FDA has completed a trial, the capsule will not be approved for human use,” he wrote.

The company says the capsule is a first-in-class anti-carcinogenic capsule, and that it has not received any adverse reactions.

The FDA did not immediately respond to a request for comment.